Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Accenture
US Army
Covington
Novartis
McKesson
UBS
QuintilesIMS
Julphar
Citi

Generated: October 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,110,918

« Back to Dashboard

Which drugs does patent 6,110,918 protect, and when does it expire?


Patent 6,110,918 protects GEODON and is included in one NDA. There has been one Paragraph IV challenge on Geodon.

This patent has fifty-four patent family members in forty-three countries.

Summary for Patent: 6,110,918

Title: Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihy dro-2(1H)-indol-2-one (=ziprasidone), its preparation and its use as dopamine D2 antagonist
Abstract:Mesylate Trihydrate Salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one (=Ziprasidone), Its Preparation and Its Use as Dopamine D2 Antagonist The invention relates to the mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydr o-2(1H)-indol-2-one ("ziprasidone mesylate trihydrate"), to pharmaceutical compositions containing ziprasidone mesylate trihydrate, and to methods of administering ziprasidone mesylate trihydrate to treat psychotic diseases.
Inventor(s): Busch; Frank R. (Gales Ferry, CT), Rose; Carol A. (Ledyard, CT)
Assignee: Pfizer Inc (New York, NY)
Application Number:09/180,456
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Pfizer
GEODON
ziprasidone mesylate
INJECTABLE;INTRAMUSCULAR020919-001Jun 21, 2002RXYesYes► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,110,918

PCT Information
PCT FiledMarch 26, 1997PCT Application Number:PCT/IB97/00306
PCT Publication Date:November 13, 1997PCT Publication Number: WO97/42190

International Patent Family for Patent: 6,110,918

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Turkey9802241► Subscribe
TunisiaSN97073► Subscribe
Slovakia282674► Subscribe
Slovakia150598► Subscribe
Slovenia0904273► Subscribe
Portugal904273► Subscribe
Poland188164► Subscribe
Poland329880► Subscribe
African Intellectual Property Organization (OAPI)10908► Subscribe
New Zealand508303► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Chubb
McKesson
Harvard Business School
Accenture
Baxter
QuintilesIMS
Deloitte
Mallinckrodt
Colorcon
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot